Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism, and EGFR expression for optically guided identification of orthotopic glioma

Clinical Cancer Research

Volumn 23, Issue 9, 2017, Pages 2203-2212

  Elliott, Jonathan T ^a   Marra, Kayla ^a   Evans, Linton T ^b   Davis, Scott C ^a   Samkoe, Kimberley S ^c   Feldwisch, Joachim ^d   Paulsen, Keith D ^a   Roberts, David W ^b   Pogue, Brian W ^a  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABY 029; AMINOLEVULINIC ACID; COMPOUND IRDYE680RD; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; GADOLINIUM PENTETATE; PROTOPORPHYRIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GENOTYPE; GLIOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MULTIMECHANISTIC FLUORESCENCE CONTRAST INDEX; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PHYSICAL PARAMETERS; PORPHYRIN METABOLISM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TISSUE PERFUSION; TUMOR TO BACKGROUND RATIO; WILD TYPE; ANIMAL; DIAGNOSTIC IMAGING; ENDOSCOPIC SURGERY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; PEPTIDE FRAGMENTS; PROTOPORPHYRINS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VIDEO-ASSISTED SURGERY;

EID: 85018414613     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1400     Document Type: Article

References (37)

1. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, et al. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System TumorsDiagnosed in the United States in 2008-2012. Neuro Oncol 2016;18 Suppl 1:i1-i50.
2. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62:564-76.
3. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-8.
4. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-18.
5. SchabelMC. A unified impulse responsemodel for DCE-MRI.Magn Reson Med 2012;68:1632-46.
6. Elliott JT, Samkoe KS, Davis SC, Gunn JR, Paulsen KD, Roberts DW, et al. Image-derived arterial input function for quantitative fluorescence imaging of receptor-drug binding in vivo. J Biophotonics 2016;9:282-95.
7. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32: 1323-9.
8. Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, et al. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res 2012;72:4318-28.
9. Samkoe KS, Tichauer KM, Gunn JR, Wells WA, Hasan T, Pogue BW. Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res 2014;74:7465-74.
10. Krishnaswamy V, Elliott JT,McClatchyDMIII, Barth RJ Jr, Wells WA, Pogue BW, et al. Structured light scatteroscopy. J Biomed Opt 2014;19:070504.
11. Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Lowik CW, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol 2011;104:323-32.
12. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013;10:507-18.
13. LeRoux PD, Winter TC, Berger MS, Mack LA, Wang K, Elliott JP. A comparison between preoperative magnetic resonance and intraoperative ultrasound tumor volumes and margins. J Clin Ultrasound 1994; 22:29-36.
14. Baker KJ. Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. Proc Soc Exp Biol Med 1966;122:957-63.
15. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescenceguided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000;93:1003-13.
16. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
17. Valdes PA, Leblond F, Kim A, Harris BT, Wilson BC, Fan X, et al. Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 2011;115:11-7.
18. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997;79:2282-308.
19. Samkoe KS, Gunn JR, Marra K, Hull SM, Moodie KL, Feldwisch J, et al. Toxicity and pharmacokinetic profile for single dose injection of ABY-029: a fluorescent anti-EGFR synthetic Affibody molecule for human use. Mol Imag Biol (under review, 2016).
20. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
21. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005;7:7-16.
22. Sexton K, Tichauer K, Samkoe KS, Gunn J, Hoopes PJ, Pogue BW. Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One 2013;8:e60390.
23. Pichlmeier U, Bink A, Schackert G, Stummer W, ALA Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008;10:1025-34.
24. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12:745-60.
25. Kroon D-J. B-spline grid, image, and point based Registration. TheMathWorks File Exchange; 2008. Available from: https://www. mathworks.com/matlabcentral/fileexchange/20057.
26. Elliott JT, Dsouza AV, Davis SC, Olson JD, Paulsen KD, Roberts DW, et al. Review of fluorescence guided surgery visualization and overlay techniques. Biomed Opt Express 2015;6:3765-82.
27. Petrecca K, GuiotMC, Panet-RaymondV,SouhamiL. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 2013;111:19-23.
28. Fidel J,KennedyKC,DernellWS,HansenS,WissV, StroudMR, etal.Preclinical validation of the utility of BLZ-100 in providing fluorescence contrast for imaging spontaneous solid tumors. Cancer Res 2015;75:4283-91.
29. Butte PV, Mamelak A, Parrish-Novak J, Drazin D, Shweikeh F, Gangalum PR, et al. Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors. Neurosurg Focus 2014;36:E1.
30. Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 2007;6:1230-8.
31. Valdes PA, Leblond F, Jacobs VL, Wilson BC, Paulsen KD, Roberts DW. Quantitative, spectrally-resolved intraoperative fluorescence imaging. Sci Rep 2012;2:798.
32. Tichauer KM, Samkoe KS, Gunn JR, Kanick SC, Hoopes PJ, Barth RJ, et al. Microscopic lymph node tumor burden quantified by macroscopic dualtracer molecular imaging. Nat Med 2014;20:1348-53.
33. Tichauer KM, Samkoe KS, Sexton KJ, Hextrum SK, Yang HH, Klubben WS, et al. In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol 2011; 14:584-92.
34. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in humanmalignancies. Crit Rev Oncol Hematol 1995;19:183-232.
35. Wang D, Chen Y, Leigh SY, Haeberle H, Contag CH, Liu JT. Microscopic delineation of medulloblastoma margins in a transgenic mouse model using a topically applied VEGFR-1 probe. Transl Oncol 2012;5: 408-14.
36. Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613-22.
37. Sorensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics 2016;6: 262-71.